Dexcom Q3 revenue up 27% to $975M; raises FY2023 guidance, announces $500M buyback

DEXCOM INC

2023-Q3 EPS reported $0.69 revenue$2,587,800,000

GAAP revenue $975.0M (+27% YoY); U.S. +24%, international +33%.
GAAP operating income $205.5M (21.1% margin); non-GAAP operating income $238.9M.
Non-GAAP diluted EPS $0.50 vs $0.28 YoY; GAAP EPS $0.29.
FY2023 revenue guidance raised to $3.575-3.600B (23-24% growth); non-GAAP operating margin ~19%.
Board authorized $500M share repurchase program; cash and securities $3.24B.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

DEXCOM INC reported the quarter ended September 30, 2023 results: revenue $975.0 million, net income $120.7 million, or $0.29 per diluted share, EPS $0.29 per diluted share. Guidance raised.

Period: the quarter ended September 30, 2023
Revenue: $975.0 million
Net income: $120.7 million, or $0.29 per diluted share
EPS: $0.29 per diluted share
Guidance: raised
Result: reported results

Exact text from the filing

financial results as of and for the quarter ended September 30, 2023. Third Quarter 2023 Financial Highlights: • Revenue grew 27% versus the same quarter of the prior year to $975.0 million on a reported basis and 26% on an organic 1 basis. • U.S. revenue growth of 24% and international revenue growth of 33% on a reported basis. International revenue growth was 30%

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

DEXCOM INC filing history →

Source: SEC EDGAR

accession 0001093557-23-000219

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.